Phase 1 pre-clinical trial of UNAIR-led Merah Putih Vaccine shows promising result

0
418
Prof. Dr. Fedik Abdul Rantam drh presents UNAIR Merah Putih Vaccine research results on Friday, May 28, 2021. (Photo: Agus Irwanto)

The Coordinating Ministry for Economic Affairs and the Cabinet Secretary of the Republic of Indonesia supports the realization of the Merah Putih Vaccine led by Universitas Airlangga, which has undergone phase 1 of the pre-clinical trial.

The tremendous support is shown from a meeting discussing the development of Merah Putih Vaccine particularly undertaken with the platform used by UNAIR.

The meeting was held online and offline at the Balairua Room Management Office Campus C UNAIR, Friday afternoon, May 28, 2021. Several officials attended the meeting, including Prof. Dr. Ni Nyoman Tri Puspaningsih, M.Si., UNAIR Covid-19 Research Coordinator as well as UNAIR Vice-Rector for Research, Innovation and Community Development; Dida Gardera, ST., M.Sc, Assistant Deputy for Agro, Pharmacy, and Tourism of the Coordinating Ministry for Economic Affairs; and Sudirman, Director of PT Biotis Prima Agrisindo.

Several related officials from the Cabinet Secretary of the Republic of Indonesia, the Ministry of State-Owned Enterprises, the Ministry of Health, Drug and Food Monitoring Agency were also present.

In the meeting, the Head of the UNAIR Merah Putih Vaccine research team Prof. Dr. Fedik Abdul Rantam drh, revealed the development of the UNAIR Merah Putih vaccine has entered phase 1 of the preclinical trial and has shown good results.

“Regarding the antibody titer, the trend is very good, PA is also good, and the examination is still ongoing including immunotyping, kidney, haematology, toxicity, and total blood tests. The examination results will be used as the basis for conducting the phase 2 preclinical trial, “said Prof. Fedik.

For this reason, his team is currently preparing a phase 2 preclinical trial.

Previously, Universitas Airlangga (UNAIR) have conducted vaccine research on several platforms, such as the inactivated virus platform, the viral vector with adenovirus platform, and the peptide platform.

The three platforms are still ongoing and construction of the inactivated virus platform has been completed early to advance to preclinical trials and clinical trials.

“We hope in December it will be complete, however, it may be February or March before it included in the industrial scheme, ” he explained.

Furthermore, Prof. Fedik hoped that this research is in line with the expectations of the government and the Indonesian people, the independent development of vaccines so that the government can deal with the Covid-19 virus independently as well.

“For academics, we are optimistic that we can develop the technology to make our own vaccines. Of course, this is a start, “he said.